KeyBanc Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9
Absci Is Maintained at Overweight by Keybanc
Express News | Keybanc Maintains Overweight on Absci, Raises Price Target to $9
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Express News | Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%
Express News | Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9
Express News | Needham Reiterates Buy on Absci, Maintains $9 Price Target
Express News | Absci Corp: Files Prospectus to Offer & Resale, From Time to Time, of up to 5.7 Mln Shares of Common Stock by Selling Stockholder - SEC Filing
Absci to Participate in Upcoming Investor Conferences
AI is about to rewrite the "rules of the game" in drug development! Bank of America predicts that the first AI-designed drug will be launched within five years.
Bank of America stated that AI is fundamentally transforming the field of drug development, bringing unprecedented changes to the industry by significantly enhancing efficiency, reducing costs, and lowering failure rates.
KeyBanc Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $5
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Absci Corp's Earnings Call: Balancing Innovation and Financial Challenges
Scotiabank Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13
Absci Price Target Maintained With a $10.00/Share by Guggenheim
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $7 to $9